NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis $11.23 +0.34 (+3.12%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.89▼$11.4250-Day Range$7.25▼$11.2352-Week Range$7.11▼$12.81Volume36,945 shsAverage Volume36,440 shsMarket Capitalization$274.91 millionP/E RatioN/ADividend YieldN/APrice Target$15.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Profound Medical alerts: Email Address Profound Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside36.4% Upside$15.31 Price TargetShort InterestBearish1.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.11) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.89 out of 5 starsMedical Sector664th out of 936 stocksSurgical & Medical Instruments Industry78th out of 101 stocks 3.6 Analyst's Opinion Consensus RatingProfound Medical has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProfound Medical has only been the subject of 2 research reports in the past 90 days.Read more about Profound Medical's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.39% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in Profound Medical has recently decreased by 1.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROF. Previous Next 2.3 News and Social Media Coverage News SentimentProfound Medical has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Profound Medical this week, compared to 2 articles on an average week.Search Interest3 people have searched for PROF on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Profound Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.11) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -8.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -8.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 8.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Profound Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Profound Medical Stock (NASDAQ:PROF)Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Read More PROF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROF Stock News HeadlinesJuly 25 at 5:52 AM | msn.comThis author wrote a children's book about family medical history after discovering gene mutationJuly 25 at 4:12 AM | americanbankingnews.comProfound Medical (NASDAQ:PROF) Now Covered by Lake Street CapitalJuly 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.July 23 at 2:53 AM | msn.comScientists investigating explosion of colon cancers in young people make 'profound' discoveries about dietJuly 22, 2024 | markets.businessinsider.comBDC Capital Inc. disposes of Common Shares of Profound Medical Corp.July 20, 2024 | msn.comDocVA Virtual Medical Assistants Versus Traditional Healthcare PersonnelJuly 20, 2024 | msn.comMedical Cannabis Gains Ground as Alternative for Chronic Pain ReliefJuly 18, 2024 | globenewswire.comProfound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to FollowJuly 26, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.July 17, 2024 | americanbankingnews.comProfound Medical (NASDAQ:PROF) Upgraded by Stifel Nicolaus to BuyJuly 11, 2024 | globenewswire.comProfound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate DiseasesMay 16, 2024 | finanznachrichten.deProfound Medical Corp.: Profound Medical Annual General Meeting of Shareholders Voting ResultsMay 15, 2024 | globenewswire.comProfound Medical Annual General Meeting of Shareholders Voting ResultsMay 15, 2024 | finance.yahoo.comPROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTSMay 14, 2024 | msn.comProfound wins FDA clearance for AI support to Tulsa systemMay 14, 2024 | msn.comProfound Medical gets FDA okay for TULSA AI moduleMay 14, 2024 | financialpost.comProfound Medical Receives U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment PlanMay 14, 2024 | finance.yahoo.comProfound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment PlanSee More Headlines Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PROF CUSIPN/A CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees131Year FoundedN/APrice Target and Rating Average Stock Price Target$15.31 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,570,000.00 Net Margins-386.63% Pretax Margin-388.52% Return on Equity-70.08% Return on Assets-53.76% Debt Debt-to-Equity RatioN/A Current Ratio5.41 Quick Ratio4.73 Sales & Book Value Annual Sales$7.20 million Price / Sales38.18 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book8.77Miscellaneous Outstanding Shares24,480,000Free Float24,109,000Market Cap$274.91 million OptionableOptionable Beta0.84 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Arun Swarup Menawat MBA (Age 69)Ph.D., Chairman of the Board & CEO Comp: $435.87kMr. Rashed Dewan (Age 56)Chief Financial Officer Comp: $215.18kDr. Mathieu Burtnyk (Age 42)Chief Operating Officer Comp: $215.18kMr. Hartmut Warnken (Age 51)Chief Commercial Officer of Outside US Comp: $226.17kMs. Abbey Goodman (Age 41)Chief Commercial Officer of US Comp: $374.35kMr. Stephen KilmerInvestor RelationsMr. Jacques F. Cornet (Age 68)Senior VP & Product Leader Sonalleve Mr. Matthew Sobczyk C.A.CPA, Assistant Corporate ControllerMr. Levant TinazSoftware DeveloperMore ExecutivesKey CompetitorsPulse BiosciencesNASDAQ:PLSEEmbectaNASDAQ:EMBCPerspective TherapeuticsNYSE:CATXAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSView All CompetitorsInstitutional OwnershipRaymond James Trust N.A.Bought 10,500 shares on 7/25/2024Ownership: 0.043%Thompson Davis & CO. Inc.Bought 6,150 shares on 7/23/2024Ownership: 0.306%Silvercrest Asset Management Group LLCSold 52,000 shares on 5/16/2024Ownership: 0.061%Gagnon Securities LLCSold 12,539 shares on 5/14/2024Ownership: 6.259%Gagnon Advisors LLCBought 67,930 shares on 5/14/2024Ownership: 3.059%View All Institutional Transactions PROF Stock Analysis - Frequently Asked Questions How have PROF shares performed this year? Profound Medical's stock was trading at $8.49 at the start of the year. Since then, PROF stock has increased by 32.3% and is now trading at $11.23. View the best growth stocks for 2024 here. How were Profound Medical's earnings last quarter? Profound Medical Corp. (NASDAQ:PROF) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. The company had revenue of $1.91 million for the quarter, compared to analysts' expectations of $2.40 million. Profound Medical had a negative net margin of 386.63% and a negative trailing twelve-month return on equity of 70.08%. Who are Profound Medical's major shareholders? Top institutional investors of Profound Medical include Thompson Davis & CO. Inc. (0.31%) and Raymond James Trust N.A. (0.04%). How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROF) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Profound Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
